Latest News

Alimentary Health enters partnership with Norgine.

26th August 2011.  Alimentary Health Limited (AH), the specialty biotechnology company, today announces that it has entered into a development partnership with Norgine, a leading European specialty pharmaceutical company with a strong portfolio of internal development projects, principally in the areas of gastroenterology, hepatology and supportive care. Under the, ...


Xention Initiates Human Clinical Testing of New Atrial Fibrillation Drug.

27 July 2011.  XENTION LTD., the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced today that it has initiated phase 1 clinical development of XEN-D0103, an innovative new drug for the treatment and prevention of atrial fibrillation, the most common form of heart arrhythmia. Xention’s new agent...


Opsona Therapeutics announces Phase 1 clinical trial.

5 July 2011, DUBLIN, Ireland.  Opsona Therapeutics, a biotechnology company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases today announced that it has initiated a phase 1 clinical trial in healthy volunteers with its lead drug candidate OPN-305.  This is a first-in-human study with OPN-305. OPN-305 is a humanised IgG4 monoclonal(...


< back to home page